Placental Fas ligand expression is a mechanism for maternal immune tolerance to the fetus

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 6, 1999, Pages 2188-2194

  Kauma, Scott W ^a   Huff, Thomas F ^a   Hayes, Natalie ^a   Nilkaeo, Athip ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; FETOPLACENTAL UNIT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; SYNCYTIOTROPHOBLAST; TROPHOBLAST;

EID: 0033304910     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.6.2188     Document Type: Article

References (32)

1. Immune recognition, genetic regulation, and the life of the fetus
2. Implantation and the placenta: Key pieces of the development puzzle
3. Immunologic testing and immunotherapy in recurrent spontaneous abortion
4. Immunogestosis: A new etiologic concept of essential EPH gestosis with special consideration of the primagravid patient
5. Fas and Fas ligand: A death factor, and its receptor
6. Metalloproteinase-mediated release of human Fas ligand
7. Expression of the Fas ligand in cells of T-cell lineage
8. A role for CD 95 ligand in preventing graft rejection
9. Fas ligand-induced apoptosis as a mechanism of immune privilege
10. The Fas death factor
11. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice
12. Expression of the apoptosis inducing Fas Ligand in human first, and third trimester placenta and choriocarcinoma cells
13. Immunohistological characterization of the decidual leukocytic infiltrate related to endometrial gland epithelium in early human pregnancy
14. Progressive rise in the expression of interleukin-6 in human endometrium during menstrual cycle is initiated during the implantation window
15. Interleukin-1β (IL-1β), HLA-DRα, and transforming growth factor-β (TGF-β) expression in endometrium, placenta, and placental membranes
16. The mediators of inflammation (interleukin-1, interferon-α, and tumor necrosis factor) and their relevance to rejection
17. Public determinants of HLA indicated by pregnancy antibodies
18. Anti-trophoblast antibody responses during normal human pregnancy
19. Antigen expression by trophoblast populations in the human placenta and their possible immunobiological relevance
20. Expression and possible function of the HLA-G α chain in human cytotrophoblasts
21. Protection from natural killer cell-mediated lysis by HLA-G expression on target cells
22. Transforming growth factor-β is a potent immunosuppressive agent that inhibits IL-1 dependent lymphocyte proliferation
23. Transforming growth factor-β inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T-cells
24. Effects of transforming growth factor-β on the functions of natural killer cells; depressed cytolytic activity and blunting of interferon responsiveness
25. Deactivation of macrophages by transforming growth factor-β
26. Differential actions of progesterone and cortisol on lymphocyte and monocyte interaction during lymphocyte activation-relevance to immunosuppression in pregnancy
27. Macrophages synthesize and release prostaglandins in response to inflammatory stimuli
28. Immune regulation by eicosanoids
29. Immunobiology of the feto-maternal Interface
30. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins
31. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and conceptus
32. Differential expression of Fas and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils